Previous 10 | Next 10 |
SOUTH SAN FRANCISCO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will host two virtual events in December to discuss the Company’s TREM2 and progranulin (PGRN) programs. The e...
SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will participate in a fireside chat at the Stifel Healthcare Conference on Tuesday, November 1...
Alector Inc. (ALEC) is expected to report $-0.65 for Q3 2023
2023-11-07 17:25:05 ET More on Alector Alector: Milestone Uncertainty Plus Lack Of Product Revenue Alector achieves target enrollment for Phase 3 dementia study Alector slips as Goldman Sachs starts at Sell on risk to lead programs Seeking Alpha’s Quan...
Achieved Q4 2023 target enrollment in pivotal INFRONT-3 Phase 3 latozinemab clinical trial with 103 symptomatic FTD-GRN participants Enrollment completed in the INVOKE-2 Phase 2 clinical trial of AL002 in individuals with early Alzheimer’s disease in Q3 2023, data readout expecte...
2023-10-27 13:59:06 ET More on Alector Alector: Milestone Uncertainty Plus Lack Of Product Revenue Alector, Inc. (ALEC) Q2 2023 Earnings Call Transcript Alector slips as Goldman Sachs starts at Sell on risk to lead programs Alector completes enrollments in mi...
--101 symptomatic FTD-GRN participants enrolled in INFRONT-3 -- SOUTH SAN FRANCISCO, Calif., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that it has achieved target enrollment in INFRON...
2023-10-26 09:49:41 ET Summary INmune Bio is a phase 2 stage biotech company focusing on Alzheimer's and other diseases with its lead asset, XPro, and its endogenous NK cell activator, INKmune. INmune's XPro has shown promising results in stabilizing Alzheimer's disease and improv...
2023-10-04 17:23:37 ET Summary Alector, Inc. is a clinical stage biotech company with no product income and a limited portfolio. The company focuses on smart development and collaborations with big pharma to compensate for its lack of product income. Alector experienced highs ...
2023-09-25 10:34:25 ET More on Alector Seeking Alpha’s Quant Rating on Alector Financial information for Alector Alector, Inc. (ALEC) Q2 2023 Earnings Call Transcript Alector: Immuno-Neurology Innovator But Wait For The Pipeline Success Alector...
News, Short Squeeze, Breakout and More Instantly...
Data from INVOKE-2, evaluating the most advanced TREM2 candidate in clinical development for early Alzheimer’s disease, on track for Q4 2024 Strengthened leadership team with key appointments: Neil Berkley, M.S., M.B.A., named Chief Business Officer; Errol De Souza, Ph.D....
Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...
2024-04-16 21:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...